Catherine Kim1, James C Slaughter2, James G Terry3, David R Jacobs4, Nisha Parikh5, Duke Appiah6, Benjamin Leader7, Molly B Moravek8, Melissa F Wellons9. 1. Departments of Medicine, Obstetrics & Gynecology, and Epidemiology, Ann Arbor, Michigan. Electronic address: cathkim@umich.edu. 2. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. 3. Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota. 5. Department of Medicine, University of California San Francisco, San Francisco, California. 6. Department of Public Health, Texas Tech University Health Sciences Center, Lubbock, Texas. 7. ReproSource Inc., Woburn, Massachusetts. 8. Department of Obstetrics & Gynecology, Ann Arbor, Michigan. 9. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
OBJECTIVE: To examine whether F2-isoprostanes, a marker of systematic oxidative stress, are associated with antimüllerian hormone (AMH), an indicator of ovarian reserve, in a population-based cohort of women of black and white ethnicities. DESIGN: Cross-sectional analysis. SETTING: Not applicable. PATIENTS: The CARDIA Women's Study, a population-based cohort. Black (n = 398) and white (n = 432) late reproductive-aged women (mean age 40 ± 3.6 years) without histories of gynecologic surgery. MAIN OUTCOME MEASURES: Log-transformed serum AMH concentrations. RESULTS: Linear regression models evaluated whether plasma F2-isoprostanes were associated with log-transformed AMH after adjustment for age, race, smoking, body mass index, and oral contraceptive pill use. Higher levels of F2-isoprostanes were associated with lower AMH levels (β -0.048 per standard deviation, 95% confidence interval -0.087, -0.01). The observed associations were stronger at younger ages (P=.04 for interaction between levels of age and F2-isoprostanes). Indicators of other steps in the oxidative stress pathway (superoxide dismutase, paraoxonase activity, oxidized low-density lipoprotein cholesterol, and carotenoids) were not associated with AMH, although lower phospholipase A2 activity (β 0.036 per standard deviation, 95% confidence interval 0.001, 0.071) was associated with lower AMH across all ages. CONCLUSION: In a population-based cohort, higher levels of F2-isoprostanes were associated with lower ovarian reserve, particularly at younger ages.
OBJECTIVE: To examine whether F2-isoprostanes, a marker of systematic oxidative stress, are associated with antimüllerian hormone (AMH), an indicator of ovarian reserve, in a population-based cohort of women of black and white ethnicities. DESIGN: Cross-sectional analysis. SETTING: Not applicable. PATIENTS: The CARDIA Women's Study, a population-based cohort. Black (n = 398) and white (n = 432) late reproductive-aged women (mean age 40 ± 3.6 years) without histories of gynecologic surgery. MAIN OUTCOME MEASURES: Log-transformed serum AMH concentrations. RESULTS: Linear regression models evaluated whether plasma F2-isoprostanes were associated with log-transformed AMH after adjustment for age, race, smoking, body mass index, and oral contraceptive pill use. Higher levels of F2-isoprostanes were associated with lower AMH levels (β -0.048 per standard deviation, 95% confidence interval -0.087, -0.01). The observed associations were stronger at younger ages (P=.04 for interaction between levels of age and F2-isoprostanes). Indicators of other steps in the oxidative stress pathway (superoxide dismutase, paraoxonase activity, oxidized low-density lipoprotein cholesterol, and carotenoids) were not associated with AMH, although lower phospholipase A2 activity (β 0.036 per standard deviation, 95% confidence interval 0.001, 0.071) was associated with lower AMH across all ages. CONCLUSION: In a population-based cohort, higher levels of F2-isoprostanes were associated with lower ovarian reserve, particularly at younger ages.
Authors: Elizabeth R Bertone-Johnson; JoAnn E Manson; Alexandra C Purdue-Smithe; Anne Z Steiner; A Heather Eliassen; Susan E Hankinson; Bernard A Rosner; Brian W Whitcomb Journal: Hum Reprod Date: 2018-06-01 Impact factor: 6.918
Authors: Lia A Bernardi; Mercedes R Carnethon; Peter J de Chavez; Deborah E Ikhena; Lisa M Neff; Donna D Baird; Erica E Marsh Journal: Obesity (Silver Spring) Date: 2016-12-07 Impact factor: 5.002
Authors: Alexandra J White; Dale P Sandler; Aimee A D'Aloisio; Frank Stanczyk; Kristina W Whitworth; Donna D Baird; Hazel B Nichols Journal: Fertil Steril Date: 2016-05-27 Impact factor: 7.329
Authors: Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Louise A Brinton; Brian L Egleston; Roni Falk; Renée T Fortner; Kathy J Helzlsouer; Annika Idahl; Rudolph Kaaks; Eva Lundin; Melissa Merritt; Charlotte Onland-Moret; Sabina Rinaldi; María-José Sánchez; Sabina Sieri; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley Tworoger; Kala Visvanathan; Vittorio Krogh; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Wei Zheng; Joanne F Dorgan Journal: Fertil Steril Date: 2017-04 Impact factor: 7.329
Authors: Atsushi Hozawa; David R Jacobs; Michael W Steffes; Myron D Gross; Lyn M Steffen; Duk-Hee Lee Journal: Clin Chem Date: 2007-01-18 Impact factor: 8.327
Authors: Keane K Lee; Stephen P Fortmann; Ann Varady; Joan M Fair; Alan S Go; Thomas Quertermous; Mark A Hlatky; Carlos Iribarren Journal: BMC Cardiovasc Disord Date: 2011-06-29 Impact factor: 2.298
Authors: Amir S Heravi; Erin D Michos; Di Zhao; Bharath Ambale-Venkatesh; Henrique Doria De Vasconcellos; Donald Lloyd-Jones; Pamela J Schreiner; Jared P Reis; Colin Wu; Cora E Lewis; James M Shikany; Stephen Sidney; Eliseo Guallar; Chiadi E Ndumele; Pamela Ouyang; Ron C Hoogeveen; Joao A C Lima; Dhananjay Vaidya; Wendy S Post Journal: J Womens Health (Larchmt) Date: 2022-06-08 Impact factor: 3.017